ID 原文 译文
8269 HHS Engages Sanofi’s Recombinant Technology for COVID-19 Vaccine 卫生与公众服务部为研发2019新型冠状病毒疫苗而调动赛诺菲的重组技术
8270 Racing to develop a vaccine against the 2019 COVID-19, 为加速开发抗击2019新型冠状病毒的疫苗，
8271 the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response has engaged Sanofi Pasteur, the vaccines global business unit of Sanofi. 美国卫生与公众服务部主管防备及应对的助理部长办公室已与赛诺菲所属的全球性疫苗公司赛诺菲巴斯德进行接触。
8272 The Biomedical Advanced Research and Development Authority (BARDA), a component of ASPR, will provide expertise and reallocated funds to support the vaccine’s development. 隶属于主管防备及应对的助理部长办公室的生物医学高级研究与开发局将提供专业技能以及重新调拨的经费来支持疫苗的研发。
8273 Sanofi will use its egg-free, recombinant DNA platform to produce a recombinant COVID-19 vaccine candidate. 赛诺菲将利用其无鸡蛋成分的基因重组技术平台来生产一种应对2019新型冠状病毒的重组候选疫苗。
8274 The technology produces an exact genetic match to proteins of the virus. 这种技术能对病毒蛋白做出精确的基因匹配。
8275 The protein’s DNA will be combined with DNA from a virus harmless to humans, and used to rapidly produce large quantities of antigen which stimulate the immune system to protect against the virus. 这种蛋白的DNA将与一种对人体无害的病毒的DNA组合，并用于快速生产大量的刺激免疫系统来抵御病毒的抗原。
8276 The antigens will be separated and collected from these cells and purified to create working stocks of vaccine for advanced development. 这些抗原将从这些细胞中经过分离和采集，并经过纯化，以产生用于进一步研发的疫苗工作原液。
8277 “Flexibility and scalability are cornerstones of rapid response to an emerging infectious disease,” said BARDA Director Rick A. Bright, Ph.D. 生物医学高级研究与开发局局长瑞克·布莱特博士表示：“灵活性和可扩展性是快速应对一种新发传染病的基石。
8278 “Using this proven technology, we can pivot immediately to address this new global health threat. 利用这种已经得到验证的技术,我们能够立即转而应对这种新型全球健康威胁。